Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Tandem Diabetes Care, Inc.

TNDM

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.

Last trade $17.32
Day change -$1.165 (-6.30%)
Day range $17.25 – $18.77
Volume 1,021,861
Market cap $1.29B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.29B
Price / earnings
—
Price / book
9.55×
Price / sales
1.2×
EV / sales
1.69×
EV / EBITDA
-248.71×

Profitability

Earnings per share
-$0.71
Return on assets
-4.25%
Return on equity
-36.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
4.47×
Current ratio
3.21×
Quick ratio
2.65×
Cash ratio
0.28×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$114.88M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TNDM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$283.69M$254.56M$247.22M$290.38M$249.25M$240.68M$234.42M$282.65M
Cost of revenue$123.27M$109.78M$110.43M$122.92M$114.96M$114.82M$116.02M$125.19M
Gross profit$160.42M$144.78M$136.79M$167.46M$134.29M$125.86M$118.41M$157.46M
Selling, general and administrative$113.95M$111.64M$108.19M$113.1M$108.44M$109.6M$113.85M$105.84M
Research and development$48.85M$46.93M$46.04M$46.07M$48.72M$48.12M$50.22M$52.2M
Total operating expenses$162.79M$158.57M$154.22M$159.17M$157.16M$177.67M$239.29M$158.04M
Operating income-$2.37M-$13.79M-$17.43M$8.29M-$22.86M-$51.81M-$120.88M-$582K
Interest expense-$2.31M-$2.45M-$2.2M-$2.08M-$2.07M-$1.91M-$1.86M-$1.86M
Income before taxes-$7.69M-$20.66M-$19.88M$4.68M-$25.14M-$57.72M-$122.09M$16K
Income taxes-$608K$510K$516K$5.27M-$3.98M-$5.32M$8.47M-$739K
Net income-$7.09M-$21.17M-$20.39M-$589K-$21.17M-$52.4M-$130.56M$755K
Net income attributable to common shareholders-$7.09M-$21.17M-$20.39M-$589K-$21.17M-$52.4M-$130.56M$755K
EBITDA$2.14M-$9.32M-$12.93M$12.79M-$18.37M-$27.49M-$41.35M$3.66M
Basic earnings per share-$0.10-$0.31-$0.30-$0.01-$0.31-$0.78-$1.97$0.01
Diluted earnings per share-$0.10-$0.31-$0.30-$0.01-$0.31-$0.78-$1.97$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say

Tandem Diabetes Care reported Q3 2026 revenue of $283.69 million, up 13.8% year-over-year and beating consensus estimates by 6.94%. EPS of -$0.10 significantly outperformed the -$0.27 estimate. International sales grew strongly at 25.8%, while supplies revenue surged 21.3%. However, pump sales in the US declined 1.7%. Despite strong recent stock performance (+20.3% over the past month), the company holds a Zacks Rank #4 (Sell) rating.

Zacks Investment Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates

Tandem Diabetes Care reported a Q3 loss of $0.1 per share, beating consensus estimates of -$0.27 loss, representing a 62.96% earnings surprise. Revenue reached $283.69 million, surpassing estimates by 6.94% and up from $249.25 million year-ago. However, the stock has underperformed the market by 13.3% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.

Zacks Investment Research

Is it the Right Time to Hold TNDM Stock in Your Portfolio?

Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026.

Zacks Investment Research

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

Tandem Diabetes (TNDM) is positioned for growth with its expanding product roadmap including the Mobi tubeless pump, new CGM integrations, and AIDANET closed-loop program. The company's pay-as-you-go reimbursement model aims to lower upfront barriers and boost recurring supply revenue. However, macroeconomic pressures, reimbursement sensitivity, competitive threats, and the impact of GLP-1 drugs on insulin therapy demand pose significant headwinds to sustained profitability.

Zacks Investment Research

Aging Population Drives Healthcare Growth: Stocks to Watch

The global aging population is reshaping healthcare investment opportunities, with the geriatric care services market projected to grow from $1.24 trillion in 2025 to $2.16 trillion by 2034. Healthcare companies are capitalizing on this demographic shift through innovations in diabetes care, cardiovascular treatments, robotic surgery, and digital health solutions. Key players like AbbVie, Tandem Diabetes Care, Amgen, Stryker, and Boston Scientific are advancing AI-enabled technologies and specialized treatments for age-related conditions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 10, 20171-for-10reverse split